Yahoo
    HKSE - Delayed Quote HKD

    Everest Medicines Limited (1952.HK)

    27.020 -0.780 (-2.81%)
    At close: November 6 at 4:08:50 PM GMT+8
    Loading Chart for 1952.HK
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Should Leadership Hire Require Action From Everest Medicines (SEHK:1952) Investors?

    Should Leadership Hire Require Action From Everest Medicines (SEHK:1952) Investors?
    Simply Wall St. 18d ago
    Everest Medicines (SEHK:1952) Gains Fresh MRNA Firepower As Undervalued View Holds

    Everest Medicines (SEHK:1952) Gains Fresh MRNA Firepower As Undervalued View Holds
    Simply Wall St. 28d ago
    Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

    Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
    PR Newswire 29d ago
    Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

    Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
    PR Newswire 29d ago
    Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults

    Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
    PR Newswire 2mo ago
    Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026

    Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
    PR Newswire 3mo ago
    Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules

    Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
    PR Newswire 4mo ago
    Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel

    Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel
    PR Newswire 4mo ago
    Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China

    Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
    PR Newswire 4mo ago
    LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

    LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
    GlobeNewswire 4mo ago
    Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market

    Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
    PR Newswire 5mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: